Wedmont Private Capital Has $988,000 Holdings in Novo Nordisk A/S (NYSE:NVO)

Wedmont Private Capital increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 3.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,450 shares of the company’s stock after acquiring an additional 330 shares during the quarter. Wedmont Private Capital’s holdings in Novo Nordisk A/S were worth $988,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of NVO. Talbot Financial LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $4,066,000. Westmount Partners LLC grew its position in Novo Nordisk A/S by 13.1% during the fourth quarter. Westmount Partners LLC now owns 2,405 shares of the company’s stock worth $207,000 after buying an additional 279 shares in the last quarter. Salem Investment Counselors Inc. increased its stake in Novo Nordisk A/S by 2.3% during the fourth quarter. Salem Investment Counselors Inc. now owns 21,926 shares of the company’s stock valued at $1,886,000 after acquiring an additional 491 shares during the period. Thomasville National Bank lifted its position in shares of Novo Nordisk A/S by 54.0% in the 4th quarter. Thomasville National Bank now owns 2,933 shares of the company’s stock worth $252,000 after acquiring an additional 1,028 shares during the period. Finally, Capital Investment Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 12.1% during the 4th quarter. Capital Investment Advisors LLC now owns 4,435 shares of the company’s stock worth $382,000 after purchasing an additional 478 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on NVO. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $84.43 on Tuesday. The stock has a market capitalization of $378.88 billion, a P/E ratio of 27.32, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a 1 year low of $81.50 and a 1 year high of $148.15. The firm has a 50 day moving average of $99.84 and a 200-day moving average of $118.61. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.